Dr Ashley Bush joins scientific advisory board at Adeona
This article was originally published in Scrip
Executive Summary
Adeona Pharmaceuticals, an Ann Arbor, Michigan-based developer of medicines for serious central nervous system diseases, has elected Dr Ashley Bush to its scientific advisory board. He is a National Health and Medical Research Council Australia Fellow and head of the oxidation disorders laboratory for the Mental Health Research Institute, University of Melbourne. Dr Bush has also served as the director of the laboratory for oxidation biology, Massachusetts General Hospital, and associate professor of psychiatry at Harvard Medical School.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.